Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma

Journal of Surgical Oncology

Volumn 73, Issue 3, 2000, Pages 148-152

  Eltabbakh, Gamal H ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Epithelial ovarian cancer; Extreme drug resistance assay; Primary peritoneal carcinoma; Response to chemotherapy

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 0034078639     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(200003)73:3<148::AID-JSO7>3.0.CO;2-U     Document Type: Article

References (13)

1. Rothaker D, Mohius G: Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: A thirty-year autopsy study. Int J Gynecol Pathol 1995;14:310-318.
2. Eltabbakh GH, Piver MS: Extraovarian primary peritoneal carcinoma. Oncology 1998;12:813-819.
3. Bloss JD, Liao SY, Buller RE, et al.: Extraovarian peritoneal serous papillary carcinoma: A case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993;50:171-174.
4. Lele SB, Piver MS, Matharu J, et al.: Peritoneal papillary carcinoma. Gynecol Oncol 1988;31:315-320.
5. Ransom DT, Chreyaskmar RP, Keeney GL, et al.: Papillary serous adenocarcinoma of the peritoneum. Cancer 1990;66:1091-1094.
6. Killackey MA, Davis AR: Papillary serous carcinoma of the peritoneal surface: Matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993;51:171-174.
7. Kern DH, Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990;82:582-588.
8. Eltabbakh GH, Piver MS, Hempling RE, et al.: Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 1998;70:392-397.
9. Cancer Committee of the International Federation of Gynecology and Obstetrics: Staging announcement, FIGO Cancer Committee. Gynecol Oncol 1986;25:383-385.
10. World Health Organization. "WHO Handbook for Reporting Results of Cancer Treatment." Geneva: World Health Organization, 1979.
11. Rustin GJS, Nelstrop ARE, Crawford M, et al.: Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA-125. J Clin Oncol 1997;15:172-176.
12. Piver MS, Eltabbakh GH, Hempling RE, et al.: Two sequential studies for primary peritoneal carcinoma: Induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol Oncol 1997;67:141-147.
13. Brown E, Markman M: Tumor chemosensitivity and chemoresistance assays. Cancer 1996;77:1020-1025.